{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:05:44Z","timestamp":1780067144971,"version":"3.54.0"},"reference-count":69,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HSS Journal\u00ae: The Musculoskeletal Journal of Hospital for Special Surgery"],"published-print":{"date-parts":[[2006,2]]},"abstract":"<jats:p>Early, aggressive disease management is critical for halting disease progression and joint destruction in patients with rheumatoid arthritis. Combination therapy with at least two disease-modifying antirheumatic drugs, such as methotrexate (MTX), sulfasalazine, or hydroxychloroquine, is often more effective than monotherapy in reducing disease activity. Biologic therapies represent more effective and tolerable treatment options that, when combined with MTX, have been shown to dramatically reduce inflammation, inhibit radiographic progression, and induce remission. Although several types of treatment strategies are used in clinical practice, the most aggressive approaches that target early disease have shown the most promise in reversing disease progression and reducing disease-related costs.<\/jats:p>","DOI":"10.1007\/s11420-005-0133-z","type":"journal-article","created":{"date-parts":[[2005,12,6]],"date-time":"2005-12-06T13:38:23Z","timestamp":1133876303000},"page":"30-41","source":"Crossref","is-referenced-by-count":18,"title":["Combination Therapy for Rheumatoid Arthritis in the Era of Biologicals"],"prefix":"10.1177","volume":"2","author":[{"given":"Allan","family":"Gibofsky","sequence":"first","affiliation":[{"name":"Departments of Medicine and Public Health, Weill Medical College of Cornell University, New York, NY, USA"},{"name":"Hospital for Special Surgery, 535 East 70th Street, 10021, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2006,2,1]]},"reference":[{"key":"bibr1-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70201-5"},{"key":"bibr2-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06075-5"},{"key":"bibr3-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.6.350"},{"key":"bibr4-s11420-005-0133-z","first-page":"585","volume":"16","author":"Fuchs HA","year":"1989","journal-title":"J Rheumatol"},{"key":"bibr5-s11420-005-0133-z","first-page":"867","volume":"16","author":"Felts W","year":"1989","journal-title":"J Rheumatol"},{"key":"bibr6-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.71.5.409"},{"key":"bibr7-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.74"},{"key":"bibr8-s11420-005-0133-z","first-page":"1792","volume":"22","author":"van der Heijde DM","year":"1995","journal-title":"J Rheumatol"},{"key":"bibr9-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.11.1157"},{"key":"bibr10-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00872-5"},{"key":"bibr11-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)01300-7"},{"key":"bibr12-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1002\/art.20351"},{"key":"bibr13-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-9-200211050-00007"},{"key":"bibr14-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1002\/art.10083"},{"key":"bibr15-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605163342002"},{"key":"bibr16-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1002\/art.10228"},{"key":"bibr17-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507203330301"},{"key":"bibr18-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.4.220"},{"key":"bibr19-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.10.1082"},{"key":"bibr20-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200008)43:8<1809::AID-ANR17>3.0.CO;2-D"},{"key":"bibr21-s11420-005-0133-z","first-page":"1493","volume":"25","author":"van den Borne BE","year":"1998","journal-title":"J Rheumatol"},{"key":"bibr22-s11420-005-0133-z","unstructured":"Enbrel\n                      \u00ae\n                      (etanercept) [package insert] (2004) Thousand Oaks, CA: Amgen Inc. and Wyeth-Ayerst Pharmaceuticals"},{"key":"bibr23-s11420-005-0133-z","unstructured":"Remicade\n                      \u00ae\n                      (infliximab) [package insert] (2003) Malvern, PA: Centacor Inc."},{"key":"bibr24-s11420-005-0133-z","unstructured":"Humira\n                      \u00ae\n                      (adalimumab) [package insert] (2003) North Chicago, IL: Abbott Laboratories"},{"key":"bibr25-s11420-005-0133-z","unstructured":"Kineret\n                      \u00ae\n                      (anakinra) [package insert] (2002) Thousand Oaks, CA; Amgen Inc."},{"key":"bibr26-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1002\/art.10141"},{"key":"bibr27-s11420-005-0133-z","first-page":"2563","volume":"30","author":"Furst DE","year":"2003","journal-title":"J Rheumatol"},{"key":"bibr28-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"bibr29-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05246-0"},{"key":"bibr30-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1002\/art.20159"},{"key":"bibr31-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"bibr32-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400401"},{"key":"bibr33-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780241012"},{"key":"bibr34-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.11.1101"},{"key":"bibr35-s11420-005-0133-z","unstructured":"Klareskog L, van der Heijde D, de Jager JP et al (2004) Clinical outcomes of a double-blind study of etanercept and methotrexate, alone and combined, in patients with active rheumatoid arthritis (TEMPO trial), year 2 results [Abstract]. Ann Rheum Dis 63"},{"key":"bibr36-s11420-005-0133-z","unstructured":"van der Heijde D, Klareskog L, Pedersen R et al (2004) Assessment of functional status among patients with active rheumatoid arthritis in a double-blind trial of etanercept and methotrexate, alone and combined (TEMPO trial) [Abstract]. Arthritis Rheum 50"},{"key":"bibr37-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1002\/art.20775"},{"key":"bibr38-s11420-005-0133-z","first-page":"1532","volume":"31","author":"Baumgartner SW","year":"2004","journal-title":"J Rheumatol"},{"key":"bibr39-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1002\/art.20568"},{"key":"bibr40-s11420-005-0133-z","unstructured":"Smolen J, van der Heijde DM, Emery P et al (2003) Methotrexate naive early rheumatoid arthritis (RA) patients with higher baseline ESR and CRP derive greater radiographic benefit from initiating treatment with a combination of infliximab and methotrexate [Abstract]. Arthritis Rheum 48"},{"key":"bibr41-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.013961"},{"key":"bibr42-s11420-005-0133-z","unstructured":"Breedveld FC, Kavanaugh AF, Cohen SB et al (2004) Early treatment of rheumatoid arthritis (RA) with adalimumab (Humira) plus methotrexate vs. adalimumab alone or methotrexate alone: the PREMIER study [Abstract]. Arthritis Rheum 50"},{"key":"bibr43-s11420-005-0133-z","first-page":"S198","volume":"21","author":"Keystone EC","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"bibr44-s11420-005-0133-z","unstructured":"Keystone EC, Kavanaugh A, Sharp J et al (2002) Adalimumab (D2E7), a fully human anti-TNF monoclonal antibody inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy [Abstract]. Arthritis Rheum 46"},{"key":"bibr45-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217"},{"key":"bibr46-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016014"},{"key":"bibr47-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.2008.i86"},{"key":"bibr48-s11420-005-0133-z","first-page":"S158","volume":"21","author":"Mullan RH","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"bibr49-s11420-005-0133-z","unstructured":"Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Zeben DV et al (2004) Treatment strategies in early rheumatoid arthritis: clinical and radiologic outcomes after 2 year follow-up of the BeST Study [Abstract]. Arthritis Rheum 50"},{"key":"bibr50-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16676-2"},{"key":"bibr51-s11420-005-0133-z","first-page":"1631","volume":"29","author":"Aletaha D","year":"2002","journal-title":"J Rheumatol"},{"key":"bibr52-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200305000-00003"},{"key":"bibr53-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)08513-4"},{"key":"bibr54-s11420-005-0133-z","unstructured":"Wolfe F, Michaud K (2004) Prednisone but not biologics or DMARDs is associated with increased risk of myocardial infarction in persons with RA [Abstract]. Ann Rheum Dis 63"},{"key":"bibr55-s11420-005-0133-z","unstructured":"Wolfe F, Michaud K (2004) Rates and risk factors for herpes zoster in patients with rheumatoid arthritis [Abstract]. Ann Rheum Dis 63"},{"key":"bibr56-s11420-005-0133-z","unstructured":"Wolfe F, Michaud K (2004) Corticosteroids increase the risk of diabetes mellitus in RA and contribute to the risk of myocardial infarction and heart failure [Abstract]. Ann Rheum Dis 63"},{"key":"bibr57-s11420-005-0133-z","first-page":"155","volume":"21","author":"van Everdingen AA","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"bibr58-s11420-005-0133-z","unstructured":"Genovese MC, Martin RW, Fleischmann RM et al (2003) Etanercept (Enbrel) in early erosive rheumatoid arthritis (ERA trial): clinical and radiographic data [Abstract]. Arthritis Rheum 47(Suppl)"},{"key":"bibr59-s11420-005-0133-z","unstructured":"Singh A, Van der Heijde D, Klareskog L et al (2004) Assessment of treatment satisfaction among patients with active rheumatoid arthritis in a double-blind trial of etanercept and methotrexate, alone and combined (TEMPO trial) [Abstract]. Arthritis Rheum 50(Suppl)"},{"key":"bibr60-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.8.764"},{"key":"bibr61-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1002\/art.20221"},{"key":"bibr62-s11420-005-0133-z","first-page":"565","volume":"16","author":"Wilske KR","year":"1989","journal-title":"J Rheumatol"},{"key":"bibr63-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1002\/art.11142"},{"key":"bibr64-s11420-005-0133-z","first-page":"12","volume":"22","author":"Fries JF","year":"1990","journal-title":"J Rheumatol, Suppl"},{"key":"bibr65-s11420-005-0133-z","first-page":"527","volume":"17","author":"Sokka TM","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"bibr66-s11420-005-0133-z","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390617"},{"key":"bibr67-s11420-005-0133-z","unstructured":"De Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Van Zeben D et al (2004) A comparison of clinical and radiologic outcomes of four treatment strategies for early rheumatoid arthritis: results of the BEST trial [Abstract]. Ann Rheum Dis 63"},{"key":"bibr68-s11420-005-0133-z","unstructured":"De Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Kerstens PJSM et al (2004) Patient preferences for treatment of newly diagnosed rheumatoid arthritis [Abstract]. Ann Rheum Dis 63"},{"key":"bibr69-s11420-005-0133-z","unstructured":"Breedveld FC et al (June 8\u201311, 2005) Presented at: EULAR Annual Meeting; Vienna, Austria. Abstract OP0013"}],"container-title":["HSS Journal\u00ae: The Musculoskeletal Journal of Hospital for Special Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1007\/s11420-005-0133-z","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11420-005-0133-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1007\/s11420-005-0133-z","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1007\/s11420-005-0133-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:48:02Z","timestamp":1777452482000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1007\/s11420-005-0133-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["10.1007\/s11420-005-0133-z"],"URL":"https:\/\/doi.org\/10.1007\/s11420-005-0133-z","relation":{},"ISSN":["1556-3316","1556-3324"],"issn-type":[{"value":"1556-3316","type":"print"},{"value":"1556-3324","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}